Intragastric injection botulinum toxin A for obesity management with or without liraglutide

dc.contributor.authorAltunal, Çetin
dc.contributor.authorŞahiner, İbrahim Tayfun
dc.contributor.authorYavuzer, Serap
dc.contributor.authorCengiz, Mahir
dc.contributor.authorSadıkoğlu, Tümay
dc.date.accessioned2023-05-30T13:08:26Z
dc.date.available2023-05-30T13:08:26Z
dc.date.issued2023en_US
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.description.abstractAbstract. – OBJECTIVE: Obesity is a global public health problem with rapidly increasing prevalence in many countries, including Turkey, and different treatment modalities have been used. This study aimed to compare the effect of intragastric botulinum toxin A (BTA) injection and BTA injection combined with low-dose liraglutide in patients with obesity. PATIENTS AND METHODS: Records of 701 patients (female/male, 660:41; mean age, 45.6 ± 6.2 years) who received an intragastric injection of BTA for weight loss between November 2019 and May 2020 were reviewed retrospectively. The patients were divided into the BTA group, which included patients who received BTA injection alone, and BTA + liraglutide, which included those who used liraglutide after BTA injection. The demographic characteristics and comorbid diseases of the patients and follow-up results 6 months after the procedure were evaluated. RESULTS: In the comparison of the 3-month and 6-month weights of the patients, weight measurements were significantly lower in the BTA + liraglutide group than in the BTA group (p < 0.001 and p < 0.001, respectively). Adverse effects were observed in 212 (30.2%) of the study participants, of which 25% were observed in the BTA group and 31.8% in the BTA + liraglutide group, with no significant difference. CONCLUSIONS: The intragastric injection of BTA combined with liraglutide is a safe method that provides more effective weight loss than BTA alone, which is minimally invasive without any serious adverse effects.
dc.description.provenanceSubmitted by Zeynep Umut NARİN (umutarslan@hitit.edu.tr) on 2023-05-30T13:08:10Z No. of bitstreams: 2 tayfun-sahiner2023.pdf: 452256 bytes, checksum: bc866f7932507ca123e8cd37a592be76 (MD5) license_rdf: 810 bytes, checksum: 73abee61e377f73f1d5fc0522cf9cde0 (MD5)en
dc.description.provenanceApproved for entry into archive by Zeynep Umut NARİN (umutarslan@hitit.edu.tr) on 2023-05-30T13:08:26Z (GMT) No. of bitstreams: 2 tayfun-sahiner2023.pdf: 452256 bytes, checksum: bc866f7932507ca123e8cd37a592be76 (MD5) license_rdf: 810 bytes, checksum: 73abee61e377f73f1d5fc0522cf9cde0 (MD5)en
dc.description.provenanceMade available in DSpace on 2023-05-30T13:08:26Z (GMT). No. of bitstreams: 2 tayfun-sahiner2023.pdf: 452256 bytes, checksum: bc866f7932507ca123e8cd37a592be76 (MD5) license_rdf: 810 bytes, checksum: 73abee61e377f73f1d5fc0522cf9cde0 (MD5) Previous issue date: 2023en
dc.identifier.citationAltunal, Ç., Sahiner, I. T., Yavuzer, S., Cengiz, M., & Sadıkoğlu, T. (2023). Intragastric injection botulinum toxin A for obesity management with or without liraglutide. Eur Rev Med Pharmacol Sci, 27(8), 3545-3551.
dc.identifier.doi10.26355/eurrev_202304_32128
dc.identifier.endpage3551en_US
dc.identifier.issn1128-3602
dc.identifier.issue8en_US
dc.identifier.pmid37140305
dc.identifier.scopusqualityQ2
dc.identifier.startpage3545en_US
dc.identifier.urihttps://hdl.handle.net/11491/8480
dc.identifier.volume27en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherVerduci Editore s.r.l
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectObesityen_US
dc.subjectBotulinum toxin type Aen_US
dc.subjectLiraglutideen_US
dc.subjectGastroscopyen_US
dc.titleIntragastric injection botulinum toxin A for obesity management with or without liraglutide
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
tayfun-sahiner2023.pdf
Boyut:
441.66 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: